Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1

Cancer Science

Volumn 102, Issue 4, 2011, Pages 742-748

  Choi, Eun Sun ^a   Shim, Jung Hyun ^b   Jung, Ji Youn ^c   Kim, Hyeong Jin ^c   Choi, Kyeong Hee ^a   Shin, Ji Ae ^a   Nam, Jeong Seok ^d   Cho, Nam Pyo ^a   Cho, Sung Dae ^a  

^a Chonbuk National University   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Kongju National University   (South Korea)

^d Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; MESSENGER RNA; MITHRAMYCIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN MCL 1; RECOMBINANT EPIDERMAL GROWTH FACTOR; SMALL INTERFERING RNA; TOLFENAMIC ACID; TRANSCRIPTION FACTOR SP1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; FRAGMENTATION REACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; TUMOR XENOGRAFT;

ANIMALS; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; IMMUNOENZYME TECHNIQUES; LUCIFERASES; MALE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952749619     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01871.x     Document Type: Article

References (24)

1. Daneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of the prostate. Cancer 1993; 71(3 Suppl): 1089-97.
2. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 419-24.
3. Wang G, Reed E, Li QQ. Apoptosis in prostate cancer: progressive and therapeutic implications (Review). Int J Mol Med 2004; 14(1): 23-34.
4. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997; 32(4): 284-93.
5. Cho SD, Jiang C, Malewicz B et al. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 2004; 3(5): 605-11.
6. Cho SD, Ahn NS, Jung JW et al. Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells. Eur J Cancer Prev 2006; 15(1): 57-63.
7. Hansen PE. Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol Toxicol 1994; 75(Suppl 2): 81-2.
8. Rejholec V, Vapaatalo H, Tokola O, Gothoni G. Tolfenamic acid in the treatment of rheumatoid arthritis. Scand J Rheumatol Suppl 1979; 24: 9-12.
9. Wankya BM, Awadh S, Mwai SJ. Tolfenamic acid and ibuprofen in rheumatoid arthritis: a double-blind cross over study. East Afr Med J 1981; 58(8): 622-5.
10. Zachariae E, Sylvest J. Osteoarthritis of the knee treated with tolfenamic acid. Scand J Rheumatol 1972; 1(3): 97-9.
11. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006; 98(12): 855-68.
12. Abdelrahim M, Baker CH, Abbruzzese JL et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007; 67(7): 3286-94.
13. Lee SH, Bahn JH, Choi CK et al. ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther 2008; 7(12): 3739-50.
14. Chu S, Ferro TJ. Sp1: regulation of gene expression by phosphorylation. Gene 2005; 348: 1-11.
15. Deniaud E, Baguet J, Mathieu AL, Pages G, Marvel J, Leverrier Y. Overexpression of Sp1 transcription factor induces apoptosis. Oncogene 2006; 25(53): 7096-105.
16. Firestone GL, Bjeldanes LF. Indole-3-carbinol and 3-3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr 2003; 133(Suppl 7): 2448S-55S.
17. Yuan H, Gong A, Young CY. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 2005; 26(4): 793-801.
18. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007; 67(6): 2816-23.
19. Huang CS, Ho WL, Lee WS et al. SP1-regulated p27/Kip1 gene expression is involved in terbinafine-induced human A431 cancer cell differentiation: an in vitro and in vivo study. Biochem Pharmacol 2008; 75(9): 1783-96.
20. Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 2008; 62(3): 444-9.
21. Jafari S, Etminan M, Afshar K. Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J 2009; 3(4): 323-30.
22. Colon J, Basha MR, Madero-Visbal R et al. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2011; 29: 41-51.
23. Konduri S, Colon J, Baker CH et al. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 2009; 8(3): 533-42.
24. Papineni S, Chintharlapalli S, Abdelrahim M et al. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009; 30(7): 1193-201.